Clinical trial Recruiting at 1 site Phase 1 Interventional Ages Any age to 22

Using fecal microbiota transplantation to treat gastrointestinal issues in children after stem cell transplants

Official title: Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).

Run by St. Jude Children's Research Hospital · NCT05664113 · Data updated 2026-11-12

This study is testing whether giving fecal microbiota transplants can help children with gut problems after they’ve had a stem cell transplant.

More Gastro-Intestinal Disorder trials

Quick facts

PhasePhase 1
Study typeInterventional
AgesAny age to 22 Years
SexAll
Enrollment10 (estimated)
SponsorSt. Jude Children's Research Hospital
Academic / other
Drugs / interventionsradiation
Locations1 site (Memphis, Tennessee)
StatusRecruiting
StartedJuly 7, 2025
Main results expectedDecember 31, 2026
Study endsDecember 31, 2028
Registry record updatedJuly 20, 2026
Trial IDNCT05664113 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children under 22 years old who have undergone HCT and are experiencing steroid-resistant or steroid-dependent gut graft-versus-host disease or prolonged gastrointestinal dysfunction.

Probably not a fit

Patients who are not experiencing gastrointestinal issues following HCT or those with certain viral infections may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the feasibility, safety, and potential efficacy of fecal microbiota transplantation (FMT) for children experiencing gastrointestinal dysfunction following hematopoietic cell transplantation (HCT). Participants aged 22 years or younger who have undergone HCT and are experiencing specific gastrointestinal symptoms will receive FMT using material from OpenBiome. The procedure involves administering FMT via a nasojejunal tube and colonoscopy, with the possibility of a second treatment if symptoms do not improve. The study aims to assess both the safety and potential benefits of this innovative approach in managing gut-related complications post-transplant.

Why it matters

Potential benefit: If successful, this treatment could significantly improve gastrointestinal health and quality of life for children recovering from HCT.

How similar studies have gone: Other studies have shown promise in using fecal microbiota transplantation for gastrointestinal disorders, suggesting potential success for this approach in similar patient populations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \< 22 years old.
* Received an allogeneic HCT greater than or equal to 30 days prior to enrollment
* Diagnosed with one of the following conditions:

  1. Steroid-resistant gut a GvHD (defined as GI symptoms that do not improve within 5 days after initial steroid therapy, \>/= 1mg/kg of prednisolone) OR
  2. Steroid-dependent gut a GvHD (defined as the presence of a response to methylprednisolone 2 mg/kg/day but relapsing when an attempt was made to taper steroid treatment).

     OR
  3. Current or prolonged GI dysfunction following HCT, defined as having diarrhea or loose stools \>/= 4 weeks with at least one of the following:

     1. Requiring NG or G-tube feeds
     2. Requiring TPN or IVF for more than 4 weeks
     3. Diagnosis of gastroparesis by GI specialist documented in the medical record
* Willing and able to provide informed assent/consent

Exclusion Criteria:

* Participant is at risk for aspiration pneumonia
* History of anaphylactic allergy to foods that are not excluded from the stool donor diet
* Female participant who is pregnant or nursing
* History of previous FMT
* Intra-abdominal surgery within 4 weeks of enrollment
* At increased risk for peritonitis: presence of intra-abdominal devices (G-or GJ-tubes are acceptable), receiving peritoneal dialysis, or ascites
* Concurrent abdominal radiation therapy
* Any acute or chronic illness/condition as well as medication that in the opinion of the investigator puts the subject at greater risk from FMT or may confound the study results.

Where it's running

  • St. Jude Children's Research Hospital
    Memphis, Tennessee, United States
    Recruiting

Study contacts

  • Principal investigator: Gabriela Maron, MD — St. Jude Children's Research Hospital
  • Study coordinator: Gabriela Maron, MD
  • Email: referrainfo@stjude.org
  • Phone: 888-226-4343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.